MaaT Pharma SA

Paris Stock Exchange MAAT.PA

MaaT Pharma SA Gross Profit Margin for the year ending December 31, 2023: 74.28%

MaaT Pharma SA Gross Profit Margin is 74.28% for the year ending December 31, 2023, a -2.64% change year over year. Gross Profit Ratio is the ratio of gross profit to net sales, indicating the percentage of revenue that exceeds the cost of goods sold and reflects the efficiency of a company in managing its production or procurement and sales.

MaaT Pharma SA Gross Profit Margin for the year ending December 31, 2022 was 76.29%, a -7.99% change year over year.
MaaT Pharma SA Gross Profit Margin for the year ending December 31, 2021 was 82.92%.
MaaT Pharma SA Gross Profit Margin for the year ending December 31, 2019 was -8.62%, a -109.46% change year over year.

Key data

Date	Gross Profit Margin	Operating Income Margin	EBT Margin	Net Income Margin

Paris Stock Exchange: MAAT.PA

MaaT Pharma SA

CEO	Mr. Herve Affagard
IPO Date	Nov. 8, 2021
Location	France
Headquarters	70 Avenue Tony Garnier
Employees	54
Sector	Health Care
Industries Biotechnology Clinical Trials Pharmaceuticals

Description

MaaT Pharma SA, a clinical stage company, engages in the research and development of microbiome biotherapies for the treatment of solid cancer tumors. Its products pipeline includes MaaT013 that has completed phase 2 clinical trials for the treatment of acute graft versus host diseases, as well as in preclinical trials to treat melanoma; MaaT033, which is in phase 1b clinical trials for the improvement of survival in patients with acute myeloid leukemia or other liquid tumors receiving allogeneic hematopoietic stem cell transplantation; and MaaT03X for the treatment of solid tumors. The company was incorporated in 2014 and is headquartered in Lyon, France.

Key trends

Past 5 years